Kura Oncology Officer Proposes $306K Share Sale

The notice also reports prior three-month sales of 12,448 common shares with an aggregate market value of $130,670.01.

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) officer Mollie Vanessa Leoni gave notice of a proposed sale of 28,802 common shares, with an aggregate market value of $305,589.22 and an approximate sale date of September 29, 2026, through Morgan Stanley Smith Barney LLC. The securities detail identifies performance stock units from the issuer dated September 27, 2026. Leoni also reported selling 12,448 common shares during the preceding three months, with an aggregate market value of $130,670.01.

Key Figures

Proposed shares for sale: 28,802 common shares Proposed sale aggregate market value: $305,589.22 Shares outstanding: 88,960,619 shares +2 more

5 metrics

Proposed shares for sale 28,802 common shares Approximate sale date: September 29, 2026

Proposed sale aggregate market value $305,589.22 Proposed sale by Mollie Vanessa Leoni

Shares outstanding 88,960,619 shares Listed in the securities information

Shares sold during preceding three months 12,448 common shares Reported sale date: September 27, 2026

Preceding three-month aggregate market value $130,670.01 Reported sales by Mollie Vanessa Leoni

Key Terms

Performance Stock Units, Rule 144, Securities To Be Sold

3 terms

Performance Stock Units financial

"Performance Stock Units"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

Rule 144 regulatory

"sales required by paragraph (e) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Securities To Be Sold financial

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did Mollie Vanessa Leoni propose to sell?

Mollie Vanessa Leoni, an officer of Kura Oncology, proposed to sell 28,802 common shares, with an aggregate market value of $305,589.22 and an approximate sale date of September 29, 2026, through Morgan Stanley Smith Barney LLC.

What prior KURA share sales are reported for Mollie Vanessa Leoni?

Leoni reported selling 12,448 common shares during the preceding three months, with an aggregate market value of $130,670.01. The reported sale date is September 27, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/29/2026 - 04:25 PM Accepted by SEC EDGAR 09/29/2026 - 04:25 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002051106
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	KURA ONCOLOGY, INC.
SEC File Number	001-37620
Address of Issuer	4930 Directors Place, Suite 500 San Diego CALIFORNIA 92121
Phone	8585008800
Name of Person for Whose Account the Securities are To Be Sold	MOLLIE LEONI
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	28802	305589.22	88960619	09/29/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/27/2026	Performance Stock Units	Issuer			28802	09/27/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MOLLIE VANESSA LEONI 4930 Directors Place, Suite 500 San Diego CA 92121	Common	09/27/2026	12448	130670.01

144: Remarks and Signature

Remarks
Date of Notice	09/29/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/19/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Mollie Leoni
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)